drugset / Trial / NCT02297594

Safety, Tolerability and PK Study of AK0529 in Healthy Human

NCT02297594 ↗

Phase 1 Completed 74 enrolled Shanghai Ark Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects

Timeline

Start
2014-10
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziresovir Small molecule — Oral